Unicycive director granted 47,941 stock units

Q: What insider transaction did UNCY director Sandeep Laumas report in this Form 4/A?

Sandeep Laumas reported receiving a grant of 47,941 restricted stock units on May 14, 2026. The RSUs are payable solely in Unicycive common stock and follow a defined vesting schedule, subject to his continued service with the company.

Q: How many restricted stock units were granted to UNCY director Sandeep Laumas and when do they vest?

Laumas was granted 47,941 restricted stock units on May 14, 2026. 19,976 RSUs vest upon grant, and 3,995 RSUs vest monthly over seven months beginning June 1, 2026, provided he continues serving Unicycive Therapeutics.

Q: What type of security did UNCY grant to director Sandeep Laumas in this transaction?

The company granted Laumas restricted stock units payable solely in Unicycive common stock. Each unit represents the right to receive one share of common stock upon vesting, following the stated vesting schedule and service condition.

Q: What are Sandeep Laumas’s reported holdings after the UNCY RSU grant?

Following the transaction, Laumas is reported to hold 47,941 restricted stock units directly. This figure reflects the entire RSU grant, including portions that vest immediately and those scheduled to vest monthly over seven months.

Q: Are the UNCY restricted stock units granted to Sandeep Laumas subject to any conditions?

Yes. Vesting of the granted RSUs is subject to Laumas’s continued service with Unicycive Therapeutics. While some units vest upon grant, the remaining monthly vesting installments depend on his ongoing service through the vesting period.

Laumas Sandeep reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 07/28/2026 - 04:15 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

4/A

Rhea-AI Filing Summary

Laumas Sandeep reported acquisition or exercise transactions in this Form 4 filing.

Unicycive Therapeutics, Inc. director Sandeep Laumas received a grant of 47,941 restricted stock units on May 14, 2026, payable solely in common stock.

Of these, 19,976 RSUs vest upon grant and 3,995 vest monthly over seven months beginning June 1, 2026, subject to his continued service; post‑grant holdings total 47,941 RSUs.

Insider Trade Summary

Grant/Award: 47,941 shares

Grant/Award 1 txn

Insider Laumas Sandeep

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units ^F1	47,941	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 47,941 contracts (Direct)

Footnotes (1)

F1. Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

Key Figures

RSUs granted: 47,941 units Immediate vesting RSUs: 19,976 units Monthly vesting RSUs: 3,995 units +2 more

5 metrics

RSUs granted 47,941 units Grant to director Sandeep Laumas on May 14, 2026

Immediate vesting RSUs 19,976 units Portion of RSU grant vesting upon grant

Monthly vesting RSUs 3,995 units RSUs vesting monthly over seven months beginning June 1, 2026

Total RSUs after grant 47,941 units Director’s RSU holdings following the reported grant

Grant price per RSU $0.0000 per unit Reported transaction price per restricted stock unit

Key Terms

Restricted Stock Units, vest, continued service

3 terms

Restricted Stock Units financial

"Represents grant of restricted stock units payable solely in common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vest financial

"19,976 shares vest upon grant and 3,995 vest monthly over 7 months"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

continued service financial

"over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did UNCY director Sandeep Laumas report in this Form 4/A?

Sandeep Laumas reported receiving a grant of 47,941 restricted stock units on May 14, 2026. The RSUs are payable solely in Unicycive common stock and follow a defined vesting schedule, subject to his continued service with the company.

How many restricted stock units were granted to UNCY director Sandeep Laumas and when do they vest?

Laumas was granted 47,941 restricted stock units on May 14, 2026. 19,976 RSUs vest upon grant, and 3,995 RSUs vest monthly over seven months beginning June 1, 2026, provided he continues serving Unicycive Therapeutics.

What type of security did UNCY grant to director Sandeep Laumas in this transaction?

The company granted Laumas restricted stock units payable solely in Unicycive common stock. Each unit represents the right to receive one share of common stock upon vesting, following the stated vesting schedule and service condition.

What are Sandeep Laumas’s reported holdings after the UNCY RSU grant?

Following the transaction, Laumas is reported to hold 47,941 restricted stock units directly. This figure reflects the entire RSU grant, including portions that vest immediately and those scheduled to vest monthly over seven months.

Are the UNCY restricted stock units granted to Sandeep Laumas subject to any conditions?

Yes. Vesting of the granted RSUs is subject to Laumas’s continued service with Unicycive Therapeutics. While some units vest upon grant, the remaining monthly vesting installments depend on his ongoing service through the vesting period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Laumas Sandeep

(Last)

(First)

(Middle)

C/O UNICYCIVE THERAPEUTICS, INC.

1975 W. EL CAMINO REAL, SUITE 204

(Street)

MOUNTAIN VIEW

CALIFORNIA

94040

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Unicycive Therapeutics, Inc. [ UNCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
05/18/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	05/14/2026		A		47,941		⁽¹⁾	⁽¹⁾	Common Stock	47,941	$0	47,941	D

Explanation of Responses:

1. Represents grant of restricted stock units payable solely in common stock of the Issuer. 19,976 shares vest upon grant and 3,995 vest monthly over 7 months beginning June 1, 2026, subject to the Reporting Person's continued service with the Issuer.

	/s/ Sandeep Laumas	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR